Last reviewed · How we verify
LB-P8
At a glance
| Generic name | LB-P8 |
|---|---|
| Sponsor | LISCure Biosciences |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC (PHASE2)
- A Study to Assess the Safety and Tolerability of LB-P6 and LB-P8 in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LB-P8 CI brief — competitive landscape report
- LB-P8 updates RSS · CI watch RSS
- LISCure Biosciences portfolio CI